Latest:
Detailing the Exploration of Plixorafenib in CNS Malignancies
Patrick Y. Wen, MD, and Karisa C. Schreck, MD, PhD, discuss the novel BRAF inhibitor plixorafenib and its ongoing evaluation in central nervous system malignancies.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Nuhad K. Ibrahim, MD
Latest:
Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer
Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.
Angela C. Hirbe, MD, PhD
Angela C. Hirbe, MD, PhD, is an associate professor of medicine in the Division of Oncology at Washington University School of Medicine.
Latest:
Dr Hirbe on Long-Term Efficacy and Safety Outcomes With Mirdametinib in Symptomatic NF1-PN
Angela C. Hirbe, MD, PhD, discusses long-term follow-up data from the phase 2b ReNeu trial evaluating mirdametinib in patients with NF1-associated symptomatic PN.
Mark Yarchoan, MD
Latest:
Efficacy vs Toxicity With Immunotherapy
Panelists discuss how dual checkpoint inhibitors demonstrate significantly higher immune-related adverse event rates (nearly 30% grade 3-4) compared with atezolizumab-bevacizumab, but this increased toxicity is accompanied by meaningfully improved response rates, and the addition of anti-CTLA4 therapy roughly doubles response rates compared with anti-PD1 monotherapy in HCC.
Alexandra Sokolova
Latest:
Dr Sokolova on the Importance of Genetic Testing in Prostate Cancer
Alexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.
Christine Lovly, MD, PhD, FASCO
Latest:
Insights on Resistance Mechanisms and Sequencing Strategies for DLL3-Targeted and ADC Therapies in ES-SCLC
Panelists discussed advances in overcoming resistance in extensive-stage small cell lung cancer, highlighting promising antibody-drug conjugates and immune-based therapies targeting DLL3 and B7-H3, including bispecific T-cell engagers and CAR T cells, while emphasizing the critical need for biomarkers to guide therapy selection and optimize combinations to improve durability, intracranial activity, and patient outcomes amid the challenges of relapse and immune evasion.
Colleen Moretti
Latest:
Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPC
The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.
Anand Jillella, MD
Anand Jillella, MD, is the J. Harold Harrison, MD Distinguished University Chair in Medicine, a professor of medicine & pediatrics, and chief of the Division of Hematology/Oncology at Augusta University Medical College of Georgia. He is also associte director of Clinical Affairs and director of the Georgia Cancer Center Clinic, Ambulatory Services, and Network and Outreach
Latest:
Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD
Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.
Michelle T. Chi, MD
Latest:
Practical Considerations for Fellows Treating VTE
Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.